Literature DB >> 27220695

Histology of debris captured by a cerebral protection system during transcatheter valve-in-valve implantation.

Tobias Schmidt1, Michael Schlüter2, Hannes Alessandrini1, Ozan Akdag1, Dimitry Schewel1, Jury Schewel1, Thomas Thielsen1, Felix Kreidel1, Ralf Bader3, Maria Romero4, Elena Ladich4, Renu Virmani4, Ulrich Schäfer1, Karl-Heinz Kuck1, Christian Frerker1.   

Abstract

OBJECTIVE: Histological analyses of debris captured by a cerebral protection system (CPS) during transcatheter valve-in-valve (VIV) procedures have not been reported.
METHODS: Fifteen consecutive patients with stenotic aortic (n=13) or mitral (n=2) surgical or transcatheter bioprostheses were treated with implantation of a transcatheter heart valve (THV) in the presence of a dual-filter CPS. Mean patient age was 75 years; mean logistic EuroSCORE was 31%. Filters were collected and histological assessment of debris was performed. Patients were followed clinically until discharge.
RESULTS: Debris captured by either or both filters was detected in all patients. Acute thrombus was the most common type of debris, found in all patients, followed in frequency by arterial wall tissue (n=12 patients (80%)), calcification (n=11 (73%)) and valve tissue (n=9 (60%)). Less frequently found were organised thrombus (n=5 (30%)), foreign material (n=4 (27%)) and myocardium (n=2 (13%)). A median of 123 debris particles per patient was detected, with a trend towards a greater median number of particles collected in proximal filters (78 vs 39, p=0.065). The average maximum particle diameter was 88 (range 56-175) µm, with a median of 20 particles ≥150 µm. No stroke or transient ischaemic attack (TIA) had occurred by the time of discharge (mean 8 days).
CONCLUSIONS: Transcatheter VIV procedures were associated with the release of particulate debris into the cerebral circulation in all patients. The type of debris suggests that debris originates predominantly from arterial and valvular passage of the THV. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  Stroke

Mesh:

Year:  2016        PMID: 27220695     DOI: 10.1136/heartjnl-2016-309597

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

Review 1.  Cerebral embolic protection devices during transcatheter aortic valve implantation: clinical versus silent embolism.

Authors:  Luis Nombela-Franco; German Armijo; Gabriela Tirado-Conte
Journal:  J Thorac Dis       Date:  2018-11       Impact factor: 2.895

2.  The current status of antiplatelet therapy in patients undergoing transcatheter aortic valve implantation.

Authors:  Wieneke Vlastra; Jan J Piek; Ronak Delewi
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

3.  Preprocedural P2Y12 inhibition and decrease in platelet count following transcatheter aortic valve replacement.

Authors:  Homam Ibrahim; Eleonora Vapheas; Binita Shah; Ahmad AlKhalil; Michael Querijero; Hasan Jilaihawi; Peter Neuburger; Cezar Staniloae; Mathew R Williams
Journal:  Catheter Cardiovasc Interv       Date:  2019-05-06       Impact factor: 2.692

4.  Safety and Efficacy of Protected Cardiac Intervention: Clinical Evidence for Sentinel Cerebral Embolic Protection.

Authors:  Ulrich Schäfer
Journal:  Interv Cardiol       Date:  2017-09

5.  Cerebral protection devices in transcatheter aortic valve replacement: a clinical meta-analysis of randomized controlled trials.

Authors:  Nelson Wang; Kevin Phan
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

6.  Meta-Analysis of Stroke and Mortality Rates in Patients Undergoing Valve-in-Valve Transcatheter Aortic Valve Replacement.

Authors:  Sascha Macherey; Max Meertens; Victor Mauri; Christian Frerker; Matti Adam; Stephan Baldus; Tobias Schmidt
Journal:  J Am Heart Assoc       Date:  2021-03-08       Impact factor: 5.501

7.  Cerebral Protection During Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic Heart Disease.

Authors:  Christian-Hendrik Heeger; Andreas Metzner; Michael Schlüter; Andreas Rillig; Shibu Mathew; Roland Richard Tilz; Peter Wohlmuth; Maria E Romero; Renu Virmani; Thomas Fink; Bruno Reissmann; Christine Lemes; Tilman Maurer; Francesco Santoro; Tobias Schmidt; Alexander Ghanem; Christian Frerker; Karl-Heinz Kuck; Feifan Ouyang
Journal:  J Am Heart Assoc       Date:  2018-06-30       Impact factor: 5.501

Review 8.  Cerebrovascular Events After Transcatheter Aortic Valve Implantation.

Authors:  German Armijo; Luis Nombela-Franco; Gabriela Tirado-Conte
Journal:  Front Cardiovasc Med       Date:  2018-07-31

9.  Final 3-year clinical outcomes following transcatheter aortic valve implantation with a supra-annular self-expanding repositionable valve in a real-world setting: Results from the multicenter FORWARD study.

Authors:  Nicolas M Van Mieghem; Stephan Windecker; Ganesh Manoharan; Johan Bosmans; Sabine Bleiziffer; Thomas Modine; Axel Linke; Werner Scholtz; Didier Tchétché; Ariel Finkelstein; Saki Ito; Ruth Eisenberg; Eberhard Grube
Journal:  Catheter Cardiovasc Interv       Date:  2021-07-31       Impact factor: 2.585

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.